A native antigen “reverse capture” microarray platform for autoantibody profiling of prostate cancer sera

Cancer sera contain antibodies that react with autologous cellular antigens. Here, we report the use of a novel native antigen‐based platform, the “reverse capture” autoantibody microarray, for identification of autoantigens against which autoantibody expression may be used to differentiate between patients with prostate cancer and benign prostate hyperplasia (BPH). Serum samples were collected at our institution from patients with BPH and patients with prostate carcinoma with similar blood prostate‐specific antigen levels. IgG was purified from individual prostate cancer sera, differentially labeled with fluorescent dyes, and competitively hybridized against purified IgG from a group of well‐characterized BPH control patients on our reverse capture microarray platform. For each experiment, we performed a two‐slide dye‐swap. Using this platform, we identified 28 unique antigen‐autoantibody reactivities that have the potential to discriminate prostate cancer from BPH. These autoantigens, with p‐values ≤0.01, can be placed into the following general categories: protein kinases, cell‐cycle regulators, cancer‐growth factors, apoptosis mediators, and transcription factors. In addition, only 1 of the 28 autoantigens remained differentially targeted by autoantibodies in post‐surgical prostate cancer patients after a minimum 1‐year follow‐up. Autoantibody profiling using this platform may be a useful tool for differentiating between malignant and benign diseases of the prostate.

[1]  A. Stromberg,et al.  Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  J. Patard,et al.  Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. , 2006, The Prostate.

[3]  S. Avrameas,et al.  Preferential recognition of the phosphorylated major linear B‐cell epitope of La/SSB 349–368aa by anti‐La/SSB autoantibodies from patients with systemic autoimmune diseases , 2006, Clinical and experimental immunology.

[4]  Weiliang Qiu,et al.  Development of a “reverse capture” autoantibody microarray for studies of antigen‐autoantibody profiling , 2006, Proteomics.

[5]  Po-ki Ho,et al.  Mammalian initiator apoptotic caspases , 2005, The FEBS journal.

[6]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[7]  T. Visakorpi,et al.  Alterations of androgen receptor in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  David E. Misek,et al.  Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. , 2004, Journal of proteome research.

[9]  A. Tramontano,et al.  Conformation and Glycosylation of a Megalin Fragment Correlate with Nephritogenicity in Heymann Nephritis 1 , 2004, The Journal of Immunology.

[10]  E. Lapointe,et al.  Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin , 2004, Arthritis research & therapy.

[11]  E. Smeland,et al.  Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display , 2004, Cancer Immunology, Immunotherapy.

[12]  Erik J. Erlandson,et al.  Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity , 2003, Proteomics.

[13]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  G A Whitmore,et al.  Power and sample size for DNA microarray studies , 2002, Statistics in medicine.

[15]  Francis D. Gibbons,et al.  Judging the quality of gene expression-based clustering methods using gene annotation. , 2002, Genome research.

[16]  S. J. Monahan,et al.  Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. , 2002, Biochemical and biophysical research communications.

[17]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[18]  D. Johnston,et al.  The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. , 2001, The Journal of urology.

[19]  T. Soussi,et al.  Detection of p73 antibodies in patients with various types of cancer: immunological characterization , 2001, British Journal of Cancer.

[20]  G. Ronquist,et al.  Autoantibodies to Prostasomes as New Markers for Prostate Cancer , 2001, Upsala journal of medical sciences.

[21]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[22]  M. Brawer,et al.  Prostate‐specific antigen: Current status , 1999, CA: a cancer journal for clinicians.

[23]  G. Núñez,et al.  Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.

[24]  M. Montenarh,et al.  p53 autoantibodies in patients with urological tumours. , 1998, British journal of urology.

[25]  E. Silbergeld,et al.  P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. , 1996, Environmental health perspectives.

[26]  A. Arnold,et al.  PRAD1/lCyclin D1 proto‐oncogene: Genomic organization, 5′ dna sequence, and sequence of a tumor‐specific rearrangement breakpoint , 1993 .

[27]  R. Hiipakka,et al.  Anti-5α-Reductase Autoantibodies in the Serum of Patients with Prostatic Cancer , 1990 .

[28]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[29]  Joshua R. Ehrlich,et al.  The 'reverse capture' autoantibody microarray:a native antigen-based platform for autoantibody profiling , 2006, Nature Protocols.

[30]  Jian-ying Zhang.  Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. , 2004, Cancer detection and prevention.

[31]  F. Hodi,et al.  MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. , 2003, Cancer immunity.

[32]  Kim-Anh Do,et al.  Fingerprinting the circulating repertoire of antibodies from cancer patients , 2003, Nature Biotechnology.

[33]  P. Lipponen,et al.  Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. , 1999, The Prostate.

[34]  L. Bonetta,et al.  CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. , 1994, Oncogene.

[35]  R. Hiipakka,et al.  Anti-5 alpha-reductase autoantibodies in the serum of patients with prostatic cancer. , 1990, The Journal of clinical endocrinology and metabolism.